Pharmacologic treatments for covid-19 patients
Methods
Protocol amendment:
As of December 14, 2022, the COVID-NMA revised its protocol and stopped including pharmacological interventions trials. The analysis presented in this page includes trials identified and included up to December 14, 2022. Ofnote, different last search date are considered by category. We provide the updated results up to last search defined next to each comparison including all identified reports through our search strategy up to this date.
meta-COVID
Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:
Summary of Main Results
Summary of the evidence for pharmacological treatment of hospitalized COVID-19 patients identified up to October 17, 2022 is available below.
For earlier editions of the summary of main results, click here
Treatment comparisons
Create and download your forest plots with the most up-to-date data here Forest plots
Access the forest plots for the 0 treatment comparisons .
Comparisons evaluating antivirals and immunomodulators with last search date December 14, 2022.
Comparisons with last search date 28 February 2022 or as stated next to each comparison.
Search studies
General characteristics of primary studies
Go to page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56
| Page: 1 / Sorted by: Most recent ↓ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
| Treatment 1 | Treatment 2 | |||||||
| NCT05041907 PLATCOV Jittamala P, medRxiv, 2022 Full text Commentary Commentary |
Public/non profit |
Remdesivir |
Standard care |
RCT | Patients with confirmed COVID-19 (mild) treated by 4 centers in Thailand (3 hospital sites) and Brazil (1 outpatient site) | N=136 |
Some concerns Details |
|
| NCT05033145 Cabral P, ResearchSquare, 2022 Full text Commentary Commentary |
Not reported/unclear |
Azvudine |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild) treated by 5 centers in Brazil | N=312 |
Some concerns Details |
|
| CTRI/2021/02/030892 Jayanthi CR, Adv Ther, 2022 Full text Commentary |
Private |
Inosine Pranobex |
Placebo |
RCT | Outpatients (68%) and inpatients (32%) with confirmed COVID-19 (mild-moderate) treated by 11 centers in India | N=416 |
Some concerns Details |
|
| IRCT20200504047298N1 Siami Z, Iran Red Crescent Med J, 2022 Full text Commentary |
Public/non profit |
Atazanavir/Ritonavir |
Lopinavir + Ritonavir |
RCT | Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Iran. | N=103 |
Some concerns Details |
|
| NCT04445467 VIRCO McMahon JH, EClinicalMedicine, 2022 Full text Full text Commentary |
Mixed |
Favipiravir |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild) treated by a single center in Australia | N=199 |
Some concerns Details |
|
| NCT04518410 ACTIV-2 Taiwo BO, Top Antivir Med, 2022 Full text |
Not reported/unclear |
SAB-185 |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild-moderate) treated by 42 centers in the USA | N=213 | N/A | |
| NCT04518410 ACTIV-2 Jilg N, Top Antivir Med, 2022 a Full text |
Not reported/unclear |
Camostat Mesilate |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild-moderate) treated by 54 centers in the USA | N=215 | N/A | |
| NCT04518410 ACTIV-2 Evering TH, Open Forum Infect Dis, 2021 Full text Commentary |
Not reported/unclear |
BRII-196 plus BRII-198 |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild-moderate) treated by multiple centers in the USA, Brazil, South Africa, Mexico, Argentina and the Philippines. | N=837 |
Some concerns Details |
|
| NCT04709835 NCT04709835, Unpublished, 2022 Full text |
Not reported/unclear |
AT-527 AT-527 550 mg |
Placebo AT-527 1100 mg |
RCT | Outpatients with confirmed COVID-19 (mild-moderate) treated by 12 centers in Canada, Greece, Ireland, Latvia, Spain, UK | N=100 |
Some concerns Details |
|
| NCT04575038 CRISIS2 CRISIS2, Unpublished, 2022 Full text |
Not reported/unclear |
Brequinar |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild) treated by 14 centers in USA. | N=115 |
Low Details |
|